BiotechTube

HSC835

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Single Umbilical Cord Blood Transplantation

Conditions

Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia

Trial Timeline

Oct 7, 2014 → Aug 29, 2016

NCT ID
NCT01930162

About HSC835

HSC835 is a phase 2 stage product being developed by Novartis for Single Umbilical Cord Blood Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01930162. Target conditions include Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia.

What happened to similar drugs?

0 of 1 similar drugs in Single Umbilical Cord Blood Transplantation were approved

Approved (0) Terminated (0) Active (1)
🔄DexmedetomidineOrion CorporationPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01930162Phase 2Completed
NCT01474681Phase 1/2Completed

Competing Products

2 competing products in Single Umbilical Cord Blood Transplantation

See all competitors
ProductCompanyStageHype Score
DexmedetomidineOrion CorporationPhase 3
37
Bone Repair Cells (BRCs)VericelPhase 1/2
18